Beijing Kangle Health Biotechnology

Kangle Weishi is a clinical-stage Chinese biotechnology company specializing in the development of recombinant protein vaccines, with a primary focus on Human Papillomavirus (HPV) prevention. The company utilizes a sophisticated Virus-Like Particle (VLP) technology platform to design and manufacture multi-valent vaccines targeting various high-risk and low-risk HPV strains. Its lead assets include a recombinant trivalent HPV vaccine and a recombinant nonavalent HPV vaccine, both of which are in late-stage clinical trials. Beyond HPV, Kangle Weishi is expanding its pipeline to include vaccines for other infectious diseases, such as COVID-19 and shingles, aiming to provide high-quality, affordable immunization solutions globally.